Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05532722 · ClinicalTrials.gov registry record · Phase 1
ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
A Phase 1 study of T-cell Large Granular Lymphocytic Leukemia, sponsored by Abcuro.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 8
- Study locations
NCT05532722: Active Phase 1 study of T-cell Large Granular Lymphocytic Leukemia, sponsored by Abcuro.
NCT05532722 is a Phase 1 study of T-cell Large Granular Lymphocytic Leukemia that is active but no longer recruiting, run by Abcuro. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05532722, a Phase 1 study of T-cell Large Granular Lymphocytic Leukemia, is active but no longer recruiting, sponsored by Abcuro.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 8
- Study locations
Study Summary
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Conditions Studied
Interventions
- DRUG ABC008
Study Locations (8)
California
- City of Hope - Duarte
- University of Southern California - Los Angeles
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
New York
- Icahn School of Medicine at Mount Sinai - New York
Ohio
- Cleveland Clinic Foundation - Cleveland
Texas
- The University of Texas M.D. Anderson Cancer Center - Houston
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
What the registry record for NCT05532722 still lists
NCT05532722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 1 condition, with T-cell Large Granular Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which ABC008 is the first listed.
NCT05532722 lists 8 locations in 6 states (California, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT05532722 about?
NCT05532722 is a clinical study titled "ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)". An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
What is the current status of trial NCT05532722?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2022-09-28. Estimated completion is 2027-09.
What conditions does trial NCT05532722 study?
This clinical trial studies the following conditions: T-cell Large Granular Lymphocytic Leukemia.
What interventions are being tested in trial NCT05532722?
The interventions under investigation include: ABC008 (DRUG).
Who is sponsoring clinical trial NCT05532722?
This trial is sponsored by Abcuro, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05532722 being conducted?
This trial has 8 study locations across California, Massachusetts, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-cell Large Granular Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05532722's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI